PubRank

David A Scheinberg

Author PubWeight™ 85.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007 3.08
2 Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007 2.60
3 Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013 2.03
4 (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med 2011 2.01
5 Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002 1.99
6 Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 1.98
7 Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008 1.98
8 Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010 1.80
9 Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 2010 1.54
10 Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 2005 1.50
11 PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One 2007 1.43
12 The promise of targeted {alpha}-particle therapy. J Nucl Med 2005 1.43
13 Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010 1.41
14 Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004 1.38
15 Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat Nanotechnol 2013 1.35
16 Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003 1.31
17 Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2008 1.28
18 Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002 1.26
19 Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007 1.23
20 A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res 2010 1.22
21 Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest 2004 1.21
22 Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev 2008 1.20
23 WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010 1.20
24 High-throughput identification of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen 2007 1.18
25 Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010 1.17
26 Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine 2010 1.12
27 Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. J Biol Chem 2012 1.10
28 Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett 2008 1.09
29 Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2007 1.08
30 A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun 2003 1.07
31 A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2003 1.07
32 Efforts to control the errant products of a targeted in vivo generator. Cancer Res 2005 1.06
33 Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004 1.06
34 Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol 2005 1.05
35 Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano 2011 1.04
36 Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006 1.02
37 Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003 0.99
38 Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst 2010 0.98
39 Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med 2004 0.97
40 Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood 2004 0.95
41 A high-throughput screen for alpha particle radiation protectants. Assay Drug Dev Technol 2010 0.95
42 Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol 2011 0.95
43 Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res 2006 0.94
44 Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009 0.93
45 Targeted nanomaterials for radiotherapy. Nanomedicine (Lond) 2007 0.92
46 Alpha particles induce apoptosis through the sphingomyelin pathway. Radiat Res 2011 0.91
47 Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. J Mol Biol 2009 0.91
48 Inhibition of human peptide deformylase disrupts mitochondrial function. Mol Cell Biol 2010 0.91
49 Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest 2007 0.90
50 Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res 2004 0.89
51 A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev Technol 2011 0.88
52 Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One 2009 0.88
53 Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc 2008 0.87
54 Radioimmunotherapy for acute leukemia. Cancer Control 2002 0.86
55 Non-natural and photo-reactive amino acids as biochemical probes of immune function. PLoS One 2008 0.85
56 Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 2012 0.85
57 Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjug Chem 2007 0.85
58 Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol 2004 0.84
59 A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther 2013 0.84
60 Immunotoxin resistance in multidrug resistant cells. Cancer Res 2003 0.83
61 Immunotherapeutic approaches for hematologic malignancies. Hematology Am Soc Hematol Educ Program 2004 0.83
62 Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem 2006 0.83
63 Deploying RNA and DNA with Functionalized Carbon Nanotubes. J Phys Chem C Nanomater Interfaces 2013 0.83
64 Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol 2003 0.82
65 Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 2002 0.81
66 Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clin Cancer Res 2005 0.81
67 Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 2003 0.80
68 Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology 2013 0.80
69 CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005 0.80
70 Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood 2005 0.79
71 Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opin Biol Ther 2013 0.79
72 Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol 2008 0.79
73 Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorg Med Chem Lett 2011 0.79
74 Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. PLoS One 2012 0.79
75 Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. J Liposome Res 2010 0.78
76 A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002 0.77
77 Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget 2013 0.75
78 Immune therapy of chronic myelogenous leukemia. Leuk Res 2005 0.75
79 Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Appl Radiat Isot 2005 0.75
80 Meeting report: drug carriers in medicine and biology. Mol Pharm 2009 0.75
81 A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest 2017 0.75